Cannabidiol Adverse Effects and Toxicity
Top Cited Papers
- 13 September 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Neuropharmacology
- Vol. 17 (10), 974-989
- https://doi.org/10.2174/1570159x17666190603171901
Abstract
Background: Currently, there is great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. Multiple preclinical and clinical studies led to FDA-approval of Epidiolex®, a purified CBD medicine formulated for oral administration for treatment of infantile refractory epileptic syndromes, by the US Food and Drug Administration in 2018. The World Health Organization is considering rescheduling cannabis and cannabinoids. CBD use around the world is expanding for diseases that lack scientific evidence of the drug’s efficacy. Preclinical and clinical studies also report adverse effects (AEs) and toxicity following CBD intake. Methods: Relevant studies reporting CBD’s AEs or toxicity were identified from PubMed, Cochrane Central, and EMBASE through January 2019. Studies defining CBD’s beneficial effects were included to provide balance in estimating risk/benefit. Results: CBD is not risk-free. In animals, CBD AEs included developmental toxicity, embryo-fetal mortality, central nervous system inhibition and neurotoxicity, hepatocellular injuries, spermatogenesis reduction, organ weight alterations, male reproductive system alterations, and hypotension, although at doses higher than recommended for human pharmacotherapies. Human CBD studies for epilepsy and psychiatric disorders reported CBD-induced drug-drug interactions, hepatic abnormalities, diarrhea, fatigue, vomiting, and somnolence. Conclusion: CBD has proven therapeutic efficacy for serious conditions such as Dravet and Lennox-Gastaut syndromes and is likely to be recommended off label by physicians for other conditions. However, AEs and potential drug-drug interactions must be taken into consideration by clinicians prior to recommending off-label CBD.Keywords
This publication has 106 references indexed in Scilit:
- The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid systemInternational Journal of Neuropsychopharmacology, 2013
- A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteersSpringerPlus, 2013
- Non‐THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro‐apoptotic effects and underlying mechanismsBritish Journal of Pharmacology, 2012
- Cannabidiol for the treatment of cannabis withdrawal syndrome: a case reportJournal of Clinical Pharmacy & Therapeutics, 2012
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophreniaTranslational Psychiatry, 2012
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and PsychopathologyNeuropsychopharmacology, 2009
- The multidrug transporter ABCG2 (BCRP) is inhibited by plant‐derived cannabinoidsBritish Journal of Pharmacology, 2007
- The Effect of Cannabidiol on Mouse Hepatic Microsomal Cytochrome P450-Dependent Anandamide MetabolismBiochemical and Biophysical Research Communications, 1993
- Inhibition of hepatic microsomal cytochrome P450 by cannabidiol in adult male rats.CHEMICAL & PHARMACEUTICAL BULLETIN, 1990
- Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. IJournal of the American Chemical Society, 1940